Due to the broad applicability of its proprietary G-Technology®, to-BBB has many options for internal development. To maximize the value of its development efforts for partners, patients and investors, to-BBB applies a multidimensional and in-depth selection procedure. Only “compound-disease-combinations” with a high clinical unmet need providing for a predictable and straightforward drug development plan by equally safeguarding patent life will be considered.
The highest development priority was assigned to “doxorubicin for brain metastases and glioma”, now being tested in a clinical phase I/IIa trial as to-BBB’s lead product 2B3-101. The second product, 2B3-201, applies methylprednisolone to combat neuroinflammation associated with several CNS indications including MS, neuropathic pain and ALS. to-BBB's third product, 2B3-301, combines the G-Technology with cyclosporin A for the treatment of patients with ischemic stroke – in collaboration with NeuroVive.
In order to support the internal product pipeline and to provide the best platform technology available to its partners, to-BBB is continuously expanding its knowledge in the blood-brain barrier field.